Mode
Text Size
Log in / Sign up

Metabolic syndrome and TyG index associated with higher in-stent restenosis risk after PCI

Metabolic syndrome and TyG index associated with higher in-stent restenosis risk after PCI
Photo by Brett Jordan / Unsplash
Key Takeaway
Consider metabolic syndrome and TyG index as potential markers for in-stent restenosis risk after PCI.

This retrospective cohort study analyzed 565 patients who underwent percutaneous coronary intervention (PCI) and had follow-up angiography. The study examined the association between metabolic syndrome (MetS), the triglyceride-glucose (TyG) index, and the risk of in-stent restenosis (ISR). The comparator was a non-MetS group.

The prevalence of MetS was significantly higher in patients who developed ISR (46.5%) compared to those who did not (21.5%). Overall, 17.5% of patients (99/565) developed ISR, and 25.8% (146/565) had MetS. In adjusted analyses, MetS was independently associated with increased ISR risk (OR 2.43, 95% CI 1.43–4.15). The TyG index was also an independent predictor (OR 2.65, 95% CI 1.55–4.52) and demonstrated good discriminatory power for ISR with an area under the curve of 0.70.

Safety and tolerability data were not reported. Key limitations include the retrospective observational design, which precludes causal inference, and the lack of reported follow-up duration. The study population was limited to patients who underwent follow-up angiography, which may introduce selection bias. Funding sources and conflicts of interest were not reported.

For practice, these findings suggest the TyG index may serve as a potential marker for ISR risk stratification in patients post-PCI. However, this utility remains speculative until confirmed by prospective studies. Clinicians should interpret these associations cautiously and not assume causality.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundIn-stent restenosis (ISR) remains a significant clinical challenge after percutaneous coronary intervention (PCI). Metabolic syndrome (MetS), characterized by a cluster of metabolic abnormalities, is increasingly recognized as a contributor to cardiovascular disease progression. This study aimed to investigate the association between MetS and the risk of ISR.MethodsWe retrospectively reviewed the clinical and laboratory data of patients who underwent PCI and had follow-up angiography. Patients were categorized into MetS and non-MetS groups. MetS for comparisons of clinical characteristics and metabolic parameters. Cox and logistic regression analysis was used to identify independent risk factors for ISR. The predictive value of the triglyceride-glucose (TyG) index was evaluated using receiver operating characteristic (ROC) curve analysis.ResultsA total of 565 patients were included, of whom 99 (17.5%) developed ISR and of whom 146 (25.8%) developed MetS. The prevalence of MetS was significantly higher in the ISR group than in the non-ISR group (46.5% vs. 21.5%). Patients with MetS had significantly higher fasting plasma glucose, triglyceride, TyG index, BMI, and blood pressure, but reduced high-density lipoprotein cholesterol. Multivariable logistic regression revealed MetS (OR = 2.43, 95% CI: 1.43–4.15) and TyG index (OR = 2.65, 95% CI: 1.55–4.52) as independent predictors of ISR. ROC analysis demonstrated that the TyG index had good discriminatory power for ISR (AUC = 0.70).ConclusionMetabolic syndrome is significantly associated with an increased risk of ISR following PCI. The TyG index may serve as a useful marker for predicting ISR in clinical practice.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.